CatalYm
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, CatalYm sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
CatalYm: 4 sponsored US clinical trials, 4 recruiting.
CatalYm sponsors 4 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Adult Solid Tumor, with 2 trials.
Upper-quartile sponsor footprint
CatalYm sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
NCT07219459
Visugromab in Cachexia International Trial
NCT07112196
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
NCT07246863
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
NCT07098988
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 4 |
Therapeutic Areas
What is open in the CatalYm pipeline
4 recruiting of 4 indexed (100% open).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Adult Solid Tumor (2 trials), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
CatalYm: open-pipeline peers nationwide
Peers matched on 4 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
CatalYm sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this CatalYm page
4 registered trials is a research-attention snapshot, not an endorsement of CatalYm or any single study.
- 4 of CatalYm's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Adult Solid Tumor is the condition CatalYm studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Adult Solid Tumor trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
CatalYm pipeline card: 4 registered trials from official public datasets.Report a data error.